Radiopharmaceuticals & Contrast Media Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The report covers Radiopharmaceuticals Market Trends and it is Segmented by radiopharmaceuticals (by type of imaging modality (SPECT (Tc-99, Tl-201, Ga-67, I-123, and other SPECTs), PET (F-18, Rb-82, and other PETs), and application (diagnostic application (SPECT applications (cardiology, neurology, thyroid, and other SPECT applications) and PET application (oncology, cardiology, neurology, and other PET applications)), therapeutic application (thyroid, lymphoma, endocrine tumors, and other therapeutic applications), contrast media (type (iodinated contrast media, gadolinium-based contrast media, microbubble contrast media, and barium-based contrast media), procedure (X-ray/computed tomography (CT), magnetic resonance imaging (MRI), and ultrasound), and applications (cardiovascular disease, oncology, gastrointestinal disorders, neurological disorders, and other indications), and geography(North America, Europe, Asia-Pacific, Middle-East and Africa, and South America). The market provides the value (in USD million) for the above-mentioned segments.

Radiopharmaceuticals & Contrast Media Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

Diagnostic Radiopharmaceuticals and Contrast Media Industry Overview

The diagnostic radiopharmaceuticals and contrast media market is moderately competitive, with a few major players dominating the global market. The presence of major market players, such as Bayer AG, GE Company (GE Healthcare), Cardinal Health Inc., Siemens Healthineers, Bracco Imaging SpA, Curium Pharma, and Guerbet Group, is increasing the overall competitive rivalry of the market. The major players are evolving through strategic alliances such as acquisitions, mergers, partnerships, collaborations, new product launches, and investment in research and development to secure a position in a globally competitive market. For instance, in March 2020, Curium Pharma completed the acquisition of Zevacor Molecular, which is involved in the production of Strontium-82, which is used in the production of Rubidium-82 generators for cardiac PET imaging in the United States.

Diagnostic Radiopharmaceuticals and Contrast Media Market Leaders

  1. Cardinal Health Inc.

  2. Siemens Healthineers

  3. Bracco Imaging SpA

  4. GE Company (GE Healthcare)

  5. Guerbet Group

  6. *Disclaimer: Major Players sorted in no particular order
Diagnostic Radiopharmaceuticals and Contrast Media Market Concentration

Radiopharmaceuticals Market Report Snapshots

80% of our clients seek made-to-order reports. How do you want us to tailor yours?